LEO Pharma has acquired Replay, a herpes simplex virus (HSV) gene therapy platform, for $50m upfront, expanding the company’s presence in rare dermatology. The deal also includes milestone payments ...
The COBRA study is the first to compare an IL-17 receptor blocker with an IL-23 inhibitor in patients who do not respond adequately to an older biologic BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma ...
GlobalData highlighted a handful of therapeutics currently under investigation as chronic hand eczema treatments including Leo Pharma's delgocitinib cream, Sanofi and Regeneron's blockbuster biologic ...
Emirates Dermatology Society and LEO Pharma sign MoU to advance Chronic Hand Eczema awareness in UAE
The agreement was signed alongside the opening of LEO Pharma’s new office in Expo City Dubai, which marks a milestone in the company’s regional growth strategy ...
BALLERUP, Denmark & DUBLIN--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to ...
LEO Pharma A/S, a global leader in medical dermatology, today announces its scientific program for the European Society of ...
Nordic Capital has made an investment in LEO Pharma, a Danish medical dermatology company. No financial terms were disclosed. Moelis & Company served as financial advisor and Plesner acted as legal ...
Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific type of eczema. Called “Talk to the Hand,” this campaign aims to spread ...
Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value Rights Total Transaction Value of up to $36 million Transaction Expected to Close ...
Danish drugmaker Leo Pharma is yet to discuss the next steps for its eczema prospect temtokibart. Leo Pharma has shared phase 2b data on its eczema prospect temtokibart, reporting that the top three ...
The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.
(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results